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ABSTRACT 
Polycystic Ovary Syndrome (PCOS) is the most common, yet complex, endocrine disorder affecting women in their reproductive years and is a 
leading cause of infertility. This disease appears to be multifactorial and polygenic in nature involving multisystem dysfunction, namely 
reproduction, endocrine and metabolic. Hyperandrogenism and insulin resistance appear to be central cause to the pathophysiology of the 
disease. The glucose and insulin metabolism pathways have been studied and debated to understand whether Insulin Resistance is due to a 
defect in insulin action or a primary defect in β-cell function or decreased hepatic clearance of insulin, or a combination of all these factors. 
Numerous studies have demonstrated that obese, normal weight and thin women with PCOS have a form of insulin resistance that is unique and 
intrinsic to the disorder. Moreover obese women with PCOS possess an additional burden of insulin resistance resulting from their excess 
adiposity. Hyperinsulinemia leads to increase in androgen production directly by acting as a co-gonadotropin, augmenting Luteinizing Hormone 
activity within the ovary, and indirectly by increasing serum LH pulse amplitude. Whereas Androgens may in turn contribute at least partially to 
the insulin resistance state linked with PCOS.  In this review, we will briefly study the role of insulin resistance in polycystic ovary syndrome. 
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Introduction 
Polycystic Ovary Syndrome (PCOS) is the most common, yet 
complex, endocrine disorder affecting women in their 
reproductive years and is a leading cause of infertility 1, 2. 
The pathophysiology of PCOS is a highly debated and 
complex topic. PCOS is manifested clinically by a 
combination of ovulatory dysfunction, hyper androgenic 
state and abnormal ovarian morphology.  This disease 
appears to be multifactorial and polygenic in nature 
involving multisystem dysfunction, namely reproduction, 
endocrine and metabolic. Hyperandrogenism and insulin 
resistance appear to be central cause to the pathophysiology 
of the disease. The  incidence of disease with various 
symptoms also presents various risks like endometrial 
hyperplasia and endometrial cancer, insulin resistance / type 
2 DM, high blood pressure, dyslipidaemia, cardiovascular 
disease, strokes, weight gain, miscarriages 3.In the clinical 
scenario, PCOS is conventionally described as "a young lady, 
probably obese, presenting with manifestations of  
hirsutism, oligomenorrhea and infertility". But renewed 
interest in PCOS has led to the realization that it involves far 
more than just the reproductive system. PCOS presents an 
early characteristic feature of the metabolic syndrome with a 
cluster of abnormalities where the combination of insulin 
resistance and compensatory hyperinsulinemia predisposes 
individuals to develop a high plasma triglyceride and a low 
high-density lipoprotein cholesterol concentration, high 
blood pressure and coronary heart disease 4.Therefore PCOS 
is sometimes defined as a Metabolic Syndrome (MetS) that 
includes obesity, dyslipidemia, insulin resistance, diabetes 
mellitus, hypertension and cardiac diseases 5. Furthermore, 
recent studies have focused on association of PCOS with 
malignancies like cancerous conditions of the Endometrium, 
Breast and Ovary 6, 7. Its clinical manifestation includes 
chronic anovulation, hyperandrogenic symptoms and it can 
be associated with the metabolic dysfunction in which 
hyperinsulinemia and peripheral insulin resistance are 
clinical features. The syndrome is also associated with 
dyslipidemia and acanthosis nigricans and may increase the 
risk for cardiovascular disease and hyperestrogen related 
cancers such as endometrial and breast cancers. During the 
reproductive years, PCOS is associated with significant 
reproductive morbidity including infertility, abnormal 
uterine bleeding, miscarriage and other complications of 
pregnancy 8. 
Insulin Resistance in PCOS 
Insulin, a polypeptide hormone secreted by the β - cells of 
the pancreas, plays a dominant role in maintaining glucose 
homeostasis. The classic target tissues of insulin include the 
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liver, muscle and fat. Insulin stimulates peripheral glucose 
uptake in muscle, fat tissue and induces protein synthesis, 
cell growth and differentiation. Insulin promotes glycogen 
storage and inhibits gluconeogenesis and glycogenolysis in 
the liver. It also inhibits lipolysis. The terms insulin 
sensitivity and insulin resistance generally refer to the 
actions of insulin on glucose homeostasis 9.  PCOS is 
characterized by a metabolic disorder in which 
hyperinsulinemia and peripheral insulin resistance are 
central features 10. The characteristic disturbances of insulin 
secretion and action are much more prominent in PCOS 
women with amenorrhea or anovulatory menses than in 
equally hyperandrogenic women with regular cycles 11.  
Measurements of fasting insulin, fasting glucose/fasting 
insulin ratio area under the curve (AUC) in oral glucose 
tolerance tests (OGTT), rapid intravenous glucose tolerance 
test (IVGTT) 12 and the euglycemic hyperinsulinemic clamp  
studies have explained substantial decreases in peripheral 
sensitivity to insulin in PCOS. This decrease (approximately 
35%to 40%) is of a similar magnitude to that seen in type 2 
DM. Obesity, body fat location (upper versus lower body), 
and muscle mass all have important independent effects on 
insulin sensitivity. Alterations in any of these parameters 
could potentially contribute to insulin resistance in PCOS 10. 
The characteristic disturbances of insulin secretion and 
action are much more prominent in PCOS women with 
amenorrhea or anovulatory menses than in equally 
hyperandrogenic women with regular cycles 11.  PCOS may 
occur along with insulin resistance when the cell doors do 
not respond appropriately to the normal amounts of insulin 
produced by the body. In other words, insulin ‘key’ does not 
fit well into the ‘lock’ on the cell walls. When this happens 
extra insulin is produced to increase the chances of getting 
more glucose into the cells. This results in too much insulin 
in the body 13.   Since insulin is a growth hormone, too much 
insulin promotes weight gain, mostly in the midsection 
above the belly button resembling a ‘spare tire’. If there is 
weight gain without significant changes to diet or exercise, 
excess insulin could be the culprit. If not well managed, 
elevated insulin levels may lead to type 2 diabetes as the 
insulin receptors on the cell walls become more resistant to 
insulin that results in hyperinsulinemia. Obesity, body fat 
location and muscle mass all have independent effects on 
insulin sensitivity. Alterations in any of these parameters 
could potentially contribute to insulin resistance in PCOS 10.   
Insulin Resistance (IR) and Abnormalities in 
metabolic pathways  
The glucose and insulin metabolism pathways have been 
studied and debated to understand whether Insulin 
Resistance is due to a defect in insulin action or a primary 
defect in β-cell function or decreased hepatic clearance of 
insulin, or a combination of all these factors. An intrinsic 
genetic defect in the post-receptor insulin signal 
transduction has been found in women with PCOS 14. This 
may lead to decreased insulin action and a compensatory 
increased insulin secretion from the pancreatic β-cells. 
Regarding β-cell function, some investigators have shown a 
defective glucose-stimulated insulin secretion, indicating a 
primary defect in β-cell function. Others have found an 
increased insulin response a possible compensatory 
mechanism to a peripheral defect in insulin action, and yet 
others have found unaffected acute insulin secretion.  The 
impact of hyperinsulinemia and insulin resistance was 
elucidated on reproductive and metabolic aspects of the 
syndrome. Path breaking studies have shown that the classic 
PCOS syndrome is determined by a distinct form of insulin 
resistance; however, this molecular anomaly is not 
universally present. In PCOS, increased insulin levels are 
incriminated for direct stimulation of ovarian androgens' 
production by means of the favourable action of this 
hormone to 17a-hydroxylase and to 17,20 lyase (cytochrome 
P450cl 7a) and in cytochrome P450scc 15-17.  
The most substantial advance in the field over the past 
decade has been the realization that many women with PCOS 
are resistant to insulin. Many women with PCOS have insulin 
resistance beyond that predicted by their BMI, with 50–70% 
of these women demonstrating insulin resistance by various 
measures 18. Numerous studies have demonstrated that 
obese, normal weight and thin women with PCOS have a 
form of insulin resistance that is unique and intrinsic to the 
disorder. Moreover obese women with PCOS possess an 
additional burden of insulin resistance resulting from their 
excess adiposity. The pancreas compensates for insulin 
resistance in PCOS by increasing insulin release, which 
allows for the maintenance of normal glucose tolerance 
during the early stages of the disorder 19, 20.   
Hyperinsulinemia, resulting from insulin resistance plays a 
pathogenic role in PCOS by stimulating ovarian testosterone 
production, decreasing serum sex hormone binding globulin 
concentrations, and impending ovulation 21-23. The molecular 
mechanisms of insulin resistance involve defects in the 
insulin-receptor signalling pathway in both adipocytes and 
well as in skeletal muscle 10. Further Insulin may act directly 
in the hypothalamus, the pituitary or both and thereby 
contribute to abnormal levels of gonadotropin 24. High 
insulin can also serve as a co-factor to stimulate ACTH 
mediated androgen production in the adrenal glands 25. 
When serum insulin levels in women with PCOS are 
decreased, either due to direct suppression of insulin release 
(Diazoxide) or by enhancement of peripheral insulin 
sensitivity (Metformin), circulating free testosterone 
decreases and ovulatory function enhances 26, 27, 19. Insulin 
has been shown to stimulate steroidogenesis in both 
granulosa and theca cells of the human ovary. The 
stimulation of steroidogenesis by insulin occurs in follicles 
obtained from both normal and polycystic ovaries and there 
are no obvious differences in responsiveness between the 
two types of ovaries.    
There is a marked interaction of insulin with gonadotrophins 
in stimulation of granulosa cell production of estradiol and 
progesterone. In particular, it has been observed a more than 
tenfold increase in responsiveness to LH after preincubation 
of granulosa cells with insulin. Some authors believe that this 
may be relevant to the mechanism of anovulation in PCOS 19, 
23, 28. Anovulation in PCOS is characterized by a possible 
arrest of antral follicle development at the 6–10 mm stage 
and, therefore, a failure to enter the preovulatory phase of 
the cycle. Follicular fluid steroid levels and in vitro studies of 
estradiol production by granulosa cells isolated from PCOS 
clearly demonstrated that, for the most part, these follicles 
remain steroidogenically active and indeed show evidence of 
increased aromatase activity when compared with follicles of 
similar size from ovulatory women. Therefore there is a, 
marked disparity between follicle growth and 
steroidogenesis in this condition.    
PCOS is characterized by hypersecretion of LH and insulin. 
The synergistic enhancement by insulin of LH induced 
steroidogenesis by granulosa cells could account for the 
arrest of follicle growth but enhancement of estradiol 
production 19. The outcome of the recent studies of the 
effects of LH on granulosa cells of normal and PCOS ovaries 
provide some support for this hypothesis. Granulosa cells 
from follicles of normal ovaries respond to LH only when the 
follicles have reached about 10 mm in diameter but, in 
contrast, in cells obtained from follicles as small as 4.5 mm in 
diameter from women with anovulatory PCOS respond to 
LH. Exposure to hyperinsulinemia in vivo could account for 
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this premature responsiveness to LH 29.Moreover 
hyperinsulinemia also results in elevated levels of free IGF-1 
and further human theca cells express IGF-1 receptor genes 
(as well as insulin receptor genes), which is another way in 
which androgen production is stimulated 30. In addition, free 
IGF-1 is a potent growth factor that can activate proliferation 
of ovarian cells 31.   
Association of androgens and insulin resistance  
The disorders of extreme insulin resistance are commonly 
linked with hyperandrogenism when they exist in 
premenopausal women. It has been hypothesized that 
hyperinsulinemia causes hyperandrogenism because insulin 
has a variety of direct actions on steroidogenesis in humans. 
It is suggested that if insulin is to produce ovarian 
hyperandrogenism, polycystic ovarian changes must be 
present which predispose the ovaries to secrete excess 
androgens. Insulin does not seem in vivo to have any acute 
effects on ovarian function in normal women under 
physiologic circumstances. In a recently reported case 
report, surgical removal of insulinoma from a 24 year old 
woman resulted in resolution of the clinical and biochemical 
features of PCOS after 4 months, but small change was seen 
in the ovarian ultrasound scans. It was suggested that 
obesity and associated hyperinsulinemia could be implicated 
in the development of PCOS 32.  Studies, in which insulin 
levels have been lowered with agents that either decrease 
insulin secretion (diazoxide, somatostatin) or improve 
insulin sensitivity (metformin, troglitazone), demonstrate 
decreased androgen levels as well in PCOS women.  
Abnormalities in apparent 17, 20-lyase activity have 
improved after metformin treatment in parallel with 
reduced circulating insulin levels, consistent with an insulin-
mediated stimulation of this enzyme 33. Inverse associations 
between concentrations of sex hormone binding globulin 
(SHBG) and insulin are almost consistently found. Insulin has 
a major role in regulating hepatic production of SHBG and it 
increases the biological availability of potent steroids, mainly 
testosterone, through the suppression of SHBG synthesis. 
Insulin seems to increase adrenal sensitivity to ACTH in 
hyperandrogenic women 25.  LH may act as an intermediary 
in insulin augmented hyperandrogenism. Insulin has a direct 
action on the pituitary enhancing GnRH-stimulated LH 
release, the consequent hyperandrogenism resulting from an 
increase in LH secretion. As mentioned previously, insulin 
acts alone or synergistically with LH to increase androgen 
production in the ovary. It has also been shown in severely 
overweight infertility patients that weight reduction with a 
very low calorie diet results in a decrease in LH 
concentrations, a reduction in the LH/FSH ratio, and FSH 
predominance favoring folliculogenesis. The decrease in LH 
concentrations was inversely related to the severity of 
insulin resistance 34.  Androgens may produce a mild insulin 
resistance by increasing the number of less insulin-sensitive 
type IIb skeletal muscle fibers and by inhibiting muscle 
glycogen synthase activity. The mild insulin resistance due to 
androgen administration is not at the same magnitude as 
that seen in PCOS. There were no significant changes in 
peripheral or hepatic insulin action after prolonged 
androgen suppression by the GnRHa. Modest improvements 
in insulin sensitivity have been reported with anti androgen 
therapy in less insulin resistant, less obese or non obese 
PCOS women. It has been suggested that testosterone may 
indirectly contribute to insulin resistance through facilitating 
FFA release from the abdominal fat 35. 
Conclusion  
Hyperinsulinemia leads to increase in androgen production 
directly by acting as a co-gonadotropin, augmenting LH 
activity within the ovary, and indirectly by increasing serum 
LH pulse amplitude. Whereas Androgens may in turn 
contribute at least partially to the insulin resistance state 
linked with PCOS.  In view of the similarity between the 
insulin growth factor-1 (IGF-1) and insulin receptor, insulin 
cross-activity was proposed as a mechanism for hyper 
androgenism. Stimulation of IGF-1 receptors on ovarian 
theca cells augments LH mediated androgen production by 
these cells. Insulin causes modulation of steroidogenesis via 
its own receptors present on both granulosa and theca cells. 
More peripherally, by inhibitions of hepatic synthesis, insulin 
decreases serum sex hormones-binding  globulin (SHBG) 
favoring free circulating androgens, and decreases insulin 
like  growth factor binding protin-1 (IGFBP-1) allowing more 
IGF-1 to be freely available both locally and peripherally. 
Elevated levels of androgens in the circulation, especially 
testosterone, inhibit production of hepatic sex hormone- 
binding globulin (SHBG). With decreased SHBG in 
circulation, more androgens are left free or unbound and 
therefore produce a enhanced clinical response in terms of 
hirsutism and other manifestation of excess androgen, which 
are central to PCOS.  Hence insulin resistance is an important 
contributing factor both directly as well as indirectly in 
PCOS. 
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